47 results found.

Graft-Versus-Host Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- The Natural History of Ocular Graft-Versus Host Disease.

Graft Versus Host Disease, Leukemia, or Lymphoma Clinical Trial using rituximab; fludarabine phosphate; melphalan; sirolimus; tacrolimus; allogeneic hematopoietic stem cell transplantation; indium In 111 ibritumomab tiuxetan; yttrium Y 90 ibritumomab tiuxetan; laboratory biomarker analysis

City of Hope Medical Center - Recruiting 18 years to 69 years.
- A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Non-Hodgkin Lymphoma Using Zevalin, Fludarabine and Melphalan.
rituximab; fludarabine phosphate; melphalan; sirolimus; tacrolimus; allogeneic hematopoietic stem cell transplantation; indium In 111 ibritumomab tiuxetan; yttrium Y 90 ibritumomab tiuxetan; laboratory biomarker analysis

Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disea Clinical Trial using Cyclophosphamide; rituximab; Methotrexate; Sirolimus; Cyclosporine; Doxorubicin hydrochloride; Etoposide; Fludarabine phosphate; Prednisone; Vincristine sulfate; Cytarabine; Tacrolimus; Alemtuzumab

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 74 years.
- Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders.
Cyclophosphamide; rituximab; Methotrexate; Sirolimus; Cyclosporine; Doxorubicin hydrochloride; Etoposide; Fludarabine phosphate; Prednisone; Vincristine sulfate; Cytarabine; Tacrolimus; Alemtuzumab

Graft vs Host Disease, or Graft-Versus-Host Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Collection of Saliva From Healthy Volunteers for Research.

Bronchiolitis Obliterans, Chronic Graft Versus Host Disease, Leuk Clinical Trial using Montelukast sodium; Flow cytometry; Laboratory biomarker analysis; Quality-of-life assessment

National Institutes of Health Clinical Center (CC) - Recruiting 6 years to 80 years.
- Multi-Institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic or Autologous Stem Cell Transplantation in Children and Adults.
Montelukast sodium; Flow cytometry; Laboratory biomarker analysis; Quality-of-life assessment

Bronchiolitis Obliterans, or Graft vs Host Disease Clinical Trial using Cyclosporine Inhalation Solution

National Institutes of Health Clinical Center (CC) - Recruiting 10 years to 80 years.
- Phase II Trial of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for Treatment of Bronchiolitis Obliterans.
Cyclosporine Inhalation Solution

Renal Cell Carcinoma, Graft-Versus-Host Disease, or Engraftment S Clinical Trial using Pentostatin; Sirolimus; Cyclophosphamide; Allogeneic Hematopoietic Stem Cell Transplant; Th2 Cell Transplantation; Th2 Cells in Allogeneic HSCT

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 75 years.
- Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells.
Pentostatin; Sirolimus; Cyclophosphamide; Allogeneic Hematopoietic Stem Cell Transplant; Th2 Cell Transplantation; Th2 Cells in Allogeneic HSCT

Graft vs Host Disease, Healthy, or Lymphopenia Clinical Trial using G-CSF

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 60 years.
- Use of Granulocyte Colony Stimulating Factor (G-CSF) Mobilized Leukapheresis Collections From Healthy Volunteers to Develop Improved Methods of Stem Cell and Lymphocyte Selection for Allogeneic Transplantation.
G-CSF

Graft vs Host Disease Clinical Trial using Autologous Serum Eye Drops

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients.
Autologous Serum Eye Drops

Peripheral Blood Stem Cell Transplantation, Anemia, Sickle Cell, Clinical Trial using PBMC Transplant; Alemtuzumab (Campath ); Sirolimus (Rapamune ); Cyclophosphamide (Cytoxan ); Low Dose Irradiation

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia.
PBMC Transplant; Alemtuzumab (Campath ); Sirolimus (Rapamune ); Cyclophosphamide (Cytoxan ); Low Dose Irradiation

GVHD, or Ocular Rosacea Clinical Trial using IPL

Mayo Clinic - Recruiting 18 years or older.
- Intense Pulsed Light (IPL) and Meibomian Gland Expression to Treat Ocular Rosacea Secondary to Inactive Chronic Ocular Graft Versus Host Disease (GVHD).
IPL

Graft vs Host Disease Clinical Trial

University of British Columbia - Recruiting N/A to 18 years.
- Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease.

Graft vs Host Disease Clinical Trial using Brentuximab Vedotin

Massachusetts General Hospital - Recruiting 18 years or older.
- Phase I Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft vs. Host Disease (GvHD).
Brentuximab Vedotin

Graft Versus Host Disease, Steroid Refractory GVHD, or Acute GVH Clinical Trial using Infliximab and Basiliximab

Nationwide Children's Hospital - Recruiting 6 Months to 75 years.
- Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease.
Infliximab and Basiliximab

Graft -Versus-host-disease Clinical Trial using Mesenchymal stromal cells

Karolinska Institutet - Recruiting 18 years to 80 years.
- Treatment of Oral Mucosa in Patients With Graft-versus-host Disease Following Injection of Mesenchymal Stem Cells - Human Pilot Study.
Mesenchymal stromal cells

Chronic Graft Versus Host Disease Clinical Trial using Ofatumumab

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 18 years or older.
- Ofatumumab in Combination With Glucocorticoids for Primary Therapy of Chronic Graft Versus Host Disease.
Ofatumumab

GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia Clinical Trial using milatuzumab

Immunomedics, Inc. - Recruiting 18 years or older.
- A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies.
milatuzumab

Chronic Graft Versus Host Disease, Chronic GVHD, or Complications Clinical Trial using Treg-enriched infusion; Interleukin-2

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- A Phase I Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease.
Treg-enriched infusion; Interleukin-2

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leu Clinical Trial using fludarabine phosphate; cyclosporine; sirolimus; mycophenolate mofetil; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; total-body irradiation

Fred Hutchinson Cancer Research Center - Recruiting N/A or older.
- A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-Center Trial.
fludarabine phosphate; cyclosporine; sirolimus; mycophenolate mofetil; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; total-body irradiation

Graft vs Host Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 1 year to 75 years.
- Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease.

Graft vs Host Disease, or Graft-Versus-Host Disease Clinical Trial using Pomalidomide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 75 years.
- A Randomized Phase 2 Single-Center Study of Pomalidomide for Chronic GvHD.
Pomalidomide

Oral Chronic Graft vs Host Disease Clinical Trial using Clobetasol Oral Rinse; Chronic GVHD organ staging; Assessment of Oral GVHD; Numeric rating scales for oral pain; Oral Global Scale; Painometer (POM) Assessment; Oral Health Impact Profile-OHIP-14; Biopsy of buccal mucosa; Short ACTH stimulation test

National Institutes of Health Clinical Center (CC) - Recruiting 12 years or older.
- A Randomized Double-Blind Pilot Study of Topical Clobetasol 0.05% Oral Rinse for Oral Chronic Graft-Versus-Host-Disease.
Clobetasol Oral Rinse; Chronic GVHD organ staging; Assessment of Oral GVHD; Numeric rating scales for oral pain; Oral Global Scale; Painometer (POM) Assessment; Oral Health Impact Profile-OHIP-14; Biopsy of buccal mucosa; Short ACTH stimulation test

Graft vs Host Disease Clinical Trial using Dexamethasone 0.01% Solution

National Institutes of Health Clinical Center (CC) - Recruiting 12 years or older.
- Pilot Study of Topical Dexamethasone 0.01% Solution for Prevention of Oral Chronic Graft Versus Host Disease.
Dexamethasone 0.01% Solution

Graft Versus Host Disease, or Systemic Scleroderma Clinical Trial using imatinib mesylate; rituximab; questionnaire administration

Fred Hutchinson Cancer Research Center - Recruiting 2 years or older.
- A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation.
imatinib mesylate; rituximab; questionnaire administration

Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Clinical Trial using filgrastim; allogeneic bone marrow transplantation; peripheral blood stem cell transplantation

National Cancer Institute (NCI) - Recruiting 16 years to 65 years.
- A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies.
filgrastim; allogeneic bone marrow transplantation; peripheral blood stem cell transplantation

Hematologic Malignancies Clinical Trial using UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC)

A.O. Ospedale Papa Giovanni XXIII - Recruiting 18 years to 70 years.
- UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC) FOR THE TREATMENT OF SEVERE (GRADE III-IV) STEROID-RESISTANT GRAFT VERSUS HOST DISEASE (GvHD): A PHASE I/II TRIAL.
UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC)

Chronic Gastrointestinal Graft vs Host Disease Clinical Trial using orBec; Placebo

Soligenix - Recruiting 18 years or older.
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBecr (Oral Beclomethasone 17,21-Dipropionate) Administered as Monotherapy in the Treatment of Upper Gastrointestinal (GI) Symptoms Caused by GVHD in Patients With Chronic GI GVHD.
orBec; Placebo

Bronchiolitis Obliterans, Constructive Bronchiolitis, or Graft Ve Clinical Trial using Inhaled Cyclosporine Solution

National Institutes of Health Clinical Center (CC) - Recruiting 10 years to 80 years.
- Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans.
Inhaled Cyclosporine Solution

Graft vs Host Disease Clinical Trial using T-Guard

Xenikos - Recruiting 18 years or older.
- A Phase I/II Multicentric Study to Determine the Safety and Efficacy of a Combination of Anti-CD3 & Anti-CD7 Ricin A Immunotoxins (T-Guard) for the Treatment of Steroid-resistant Acute Graft-versus-Host Disease..
T-Guard

Poor Graft Function,, Stem Cell Transplantaion,, or Graft Versus Clinical Trial using infusion of G-CSF mobilized peripheral harvest

Peking University People's Hospital - Recruiting 14 years to 60 years.
- Infusion of Recombinant Human Granulocyte Colony Stimulating Factor Mobilized Peripheral Harvest for Poor Engraftment After Hematopoietic Stem Cell Transplantation.
infusion of G-CSF mobilized peripheral harvest

Stem Cell Leukemia of Unclear Lineage, or Graft Versus Host Disea Clinical Trial using extracorporeal photopheresis

University of Kansas - Recruiting 18 years or older.
- A Study of Extracorporeal Photopheresis With UVADEXr in the Setting of a Standard Myeloablative Conditioning Regimen in Related or Unrelated Donor Hematopoietic Stem Cell Transplantation for the Prevention of Graft Versus Host Disease.
extracorporeal photopheresis

Graft vs Host Disease Clinical Trial using Ustekinumab; Placebo

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 18 years to 70 years.
- Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation.
Ustekinumab; Placebo

Graft vs Host Disease, or Malignancy Clinical Trial using Abatacept; placebo

Emory University - Recruiting 6 years or older.
- Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial.
Abatacept; placebo

Autoimmune Diseases, Sickle Cell Disease, or Chronic Graft Versus Clinical Trial using Acoustic Radiation Force Impulse (ARFI); Laser Doppler Flowmetry (LDF); Laser Doppler Perfusion Imaging (LDI); Optical Coherence Tomography (OCT); Orthogonal Polarization Spectral Imaging (OPSI); Nail fold video capillaroscopy (NVC)

Duke University - Recruiting 18 years or older.
- Mechanistic Study: Non-Invasive Cutaneous Microvascular and Fibrosis Imaging of Patients With Systemic Sclerosis, Sickle Cell Disease and Chronic Graft-Versus-Host Disease (GVHD) Compared to Healthy Subjects.
Acoustic Radiation Force Impulse (ARFI); Laser Doppler Flowmetry (LDF); Laser Doppler Perfusion Imaging (LDI); Optical Coherence Tomography (OCT); Orthogonal Polarization Spectral Imaging (OPSI); Nail fold video capillaroscopy (NVC)

Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chr Clinical Trial using total-body irradiation; thiotepa; fludarabine phosphate; allogeneic hematopoietic stem cell transplantation; T cell-depleted hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; tacrolimus; methotrexate; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting N/A to 21 years.
- A Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children.
total-body irradiation; thiotepa; fludarabine phosphate; allogeneic hematopoietic stem cell transplantation; T cell-depleted hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; tacrolimus; methotrexate; laboratory biomarker analysis

GVHD, Adult Acute Myeloid Leukemia, Adult Acute Lymphoid Leukemia Clinical Trial using US-ATG-F; Placebo

Neovii Biotech - Recruiting 18 years to 65 years.
- Phase 3 Study of US-ATG-F to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients After Allogeneic Stem Cell Transplantation From Unrelated Donors.
US-ATG-F; Placebo

Graft vs Host Disease Clinical Trial using Tacrolimus; Cyclosporine; Methotrexate

Seoul National University Hospital - Recruiting N/A to 18 years.
- Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease in Paediatric Patients.
Tacrolimus; Cyclosporine; Methotrexate

Hematological Malignancy Clinical Trial using Cohort 1-Bortezomib (Velcade r); Cohort 2-Bortezomib (Velcade r); Cohort 3-Bortezomib (Velcade r)

Spectrum Health Hospitals - Recruiting 18 years or older.
- A Phase I Trial of Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT).
Cohort 1-Bortezomib (Velcade r); Cohort 2-Bortezomib (Velcade r); Cohort 3-Bortezomib (Velcade r)

Leukemia, Acute Myeloid, Leukemia, Lymphoblastic,Acute, or Myelod Clinical Trial using brentuximab vedotin

Washington University School of Medicine - Recruiting 18 years to 65 years.
- A Pilot Study of Brentuximab Vedotin in the Prevention of Graft-Versus-Host Disease (GVHD) After Mismatched Unrelated Allogeneic Stem Cell Transplantation.
brentuximab vedotin

Hematologic Malignancy Requiring Allogeneic Stem-cell Transplanta Clinical Trial using Maraviroc 300 mg

Abramson Cancer Center of the University of Pennsylvania - Recruiting 18 years or older.
- A Phase II Study to Assess the Efficacy of Maraviroc, a CCR5-Antagonist in Prophylaxis of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Undergoing Reduced-Intensity Allogeneic Stem-Cell Transplantation From Unrelated Donors.
Maraviroc 300 mg

Graft-versus-host Disease, or Poor Graft Function Clinical Trial using Mesenchymal stem cells

University Hospital of Liege - Recruiting N/A or older.
- Infusion of Mesenchymal Stem Cells as Treatment for Steroid-Resistant Grade II to IV Acute GVHD or Poor Graft Function: a Multicenter Phase II Study.
Mesenchymal stem cells

Graft vs Host Disease Clinical Trial using Mesenchymal stromal cells

Azienda Ospedaliera San Gerardo di Monza - Recruiting N/A or older.
- Mesenchymal Stromal Cells (MSC) for the Treatment of Severe (Grade II-IV) Steroid-resistant Graft Versus Host Disease (GVHD): a Phase I Trial.
Mesenchymal stromal cells

Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Myeloprolife Clinical Trial using ARM A Cyclophosphamide; ARM B Calcineurin inhibitor and methotrexate

Hospital Israelita Albert Einstein - Recruiting 18 years to 60 years.
- Randomized Study to Compare Post Bone Marrow Transplant Cyclophosphamide With the Combination of Methotrexate Plus Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis.
ARM A Cyclophosphamide; ARM B Calcineurin inhibitor and methotrexate

Graft Versus Host Disease, Leukemia, or Myelodysplastic Syndromes Clinical Trial using Fludarabine Phosphate; Tacrolimus; Thiotepa; Total-Body Irradiation (TBI); Magnetic Affinity Cell Sorting; Peripheral Blood Stem Cell Transplantation; Allogeneic Hematopoietic Stem Cell Transplantation; T Cell-Depleted Hematopoietic Stem Cell Transplantation

Yale University - Recruiting 14 years to 55 years.
- A Multi-center Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD.
Fludarabine Phosphate; Tacrolimus; Thiotepa; Total-Body Irradiation (TBI); Magnetic Affinity Cell Sorting; Peripheral Blood Stem Cell Transplantation; Allogeneic Hematopoietic Stem Cell Transplantation; T Cell-Depleted Hematopoietic Stem Cell Transplantation

Graft-Versus-Host Disease Clinical Trial using Multi donor stem cell transplantation

Hadassah Medical Organization - Recruiting N/A to 70 years.
- Enhancement of Hematopoietic Stem Cell Engraftment by Multi Donor Stem Cell Transplantation (MDT) From 2 Mismatched Donors, a Phase I-II Open Study.
Multi donor stem cell transplantation

Graft Versus Host Disease, Cancer, or Stem Cell Transplantation Clinical Trial using Extracorporeal Photopheresis

Ann & Robert H Lurie Children's Hospital of Chicago - Recruiting N/A to 30 years.
- Extracorporeal Photopheresis for Steroid-refractory Acute GVHD in Children and Young Adults: a Safety and Feasibility Study..
Extracorporeal Photopheresis

Acute Myeloid Leukemia, or Acute Lymphoblastic Leukemia Clinical Trial using ATG FRESENIUS (Anti-Lymphocyte-Globulin)

Universit„tsklinikum Hamburg-Eppendorf - Recruiting 18 years to 65 years.
- Prophylaxis of Chronic Graft-Versus-Host Disease (cGvHD) With or Without Anti-T-Lymphocyte-Globulin (ATG Fresenius) Prior Allogeneic Peripheral Stem Cell Transplantation From HLA-Identical Siblings After Myeloablative Conditioning in Patients With Acute Leukemia: A Randomized Phase III-Study.
ATG FRESENIUS (Anti-Lymphocyte-Globulin)